donanemab

Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Authors: John R Sims, Jennifer A Zimmer, Cynthia D Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C Collins, Paul Solomon, Stephen Salloway, Liana G Apostolova, Oskar Hansson, Craig Ritchie, Dawn A Brooks, Mark Mintun, Daniel M Skovronsky

Journal: JAMA

Year Published: 2023

Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, setting, and participants: Multicenter (277 medical research centers/hospitals in […]

Back to Publications

Cogstate
© 2025 Cogstate Ltd.

Cogstate acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the lands where many of our team members live and work. We pay respect to their Elders past and present.